Elanco Animal Health Inc. has announced that Zenrelia™ (ilunocitinib) has received approval from the European Commission, marking a significant advancement in the EU's canine dermatology market. This approval confirms Zenrelia's effectiveness and safety as a once-daily oral JAK inhibitor for managing pruritus and atopic dermatitis in dogs aged 12 months and older. The approval is a key milestone for Elanco, enhancing their position as leaders in pet health innovation. Zenrelia is already available in Brazil, Canada, Japan, and the United States, with further global approvals anticipated. The product launch in the EU will commence immediately, with availability expected by the end of Q3 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。